Work

Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer

Year: 2012

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1097/jto.0b013e31826146ee

Authors: Jasmine Foo, Juliann Chmielecki, William Pao, Franziska Michor

Institutions: University of Minnesota, Masonic Cancer Center, Dana-Farber Cancer Institute, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Harvard University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: National Cancer Institute

Awards: Overcoming acquired resistance to EGFR inhibitors in lung cancer, Targets for Therapy for Carcinomas of the Lung, Evolutionary Dynamics of Brain, Lung, and Hematopoietic Tumors, Cancer Center Support Grant

OpenAlex ID: W2141635226

FWCI: 8.954

Cites: 26

Cited by: 84

Related to: 10